tiprankstipranks
Trending News
More News >
Transgene SA (GB:0OCQ)
LSE:0OCQ

Transgene (0OCQ) Price & Analysis

Compare
2 Followers

0OCQ Stock Chart & Stats


Financials

0OCQ FAQ

What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €0.56 and its highest was €1.17 in the past 12 months.
    What is Transgene SA’s market cap?
    Transgene SA’s market cap is €104.06M.
      When is Transgene SA’s upcoming earnings report date?
      Transgene SA’s upcoming earnings report date is Sep 16, 2025 which is in 72 days.
        How were Transgene SA’s earnings last quarter?
        Currently, no data Available
        Is Transgene SA overvalued?
        According to Wall Street analysts Transgene SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Transgene SA pay dividends?
          Transgene SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Transgene SA dividends here
            What is Transgene SA’s EPS estimate?
            Transgene SA’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Transgene SA have?
            Transgene SA has 132,735,080 shares outstanding.
              What happened to Transgene SA’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Transgene SA?
              Currently, no hedge funds are holding shares in GB:0OCQ

              Company Description

              Transgene SA

              Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
              Similar Stocks
              Company
              Price & Change
              Follow
              Genfit
              Innate Pharma SA
              DBV Technologies
              Nanobiotix
              OSE Immunotherapeutics SA
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis